Table 3.

Toxicities in phase II (n = 43)

	Grade				%
	1	2	3	4	Grade 3/4 (total)
Diarrhea	19	12	4	0	9.3 (81.4)
Anorexia	12	14	5	0	11.6 (72.1)
Pruritus	21	5	0	0	0 (60.5)
Acneiform rash	16	10	0	0	0 (60.5)
Hyperglycemia	19	4	0	0	0 (53.5)
Anemia	12	8	2	0	4.7 (51.2)
Vomiting	13	6	1	0	2.3 (46.5)
Nausea	13	4	1	0	2.3 (41.9)
Fatigue	12	2	3	0	7.0 (39.5)
Oral mucositis	12	2	0	0	0 (32.6)
White blood cell count decreased	12	0	0	0	0 (27.9)
Dry skin	10	1	0	0	0 (25.6)
Hypocalcemia	8	2	0	0	0 (23.3)
ALP increased	9	1	0	0	0 (23.3)
Platelet count decreased	9	0	1	0	2.3 (23.3)
Creatinine increased	10	0	0	0	0 (23.3)
ALT increased	6	2	1	0	2.3 (20.9)
AST increased	6	2	0	0	0 (18.6)
Weight loss	4	4	0	0	0 (18.6)
Headache	4	4	0	0	0 (18.6)
Blood bilirubin increased	5	2	0	0	0 (16.3)
Hyponatremia	6	0	1	0	2.3 (16.3)
Electrocardiogram QT corrected interval prolonged	6	0	0	0	0 (14.0)
Maculopapular rash	6	0	0	0	0 5 (14.0)
Epigastric pain	0	6	0	0	0 (14.0)
Abdominal pain	2	1	3	0	7.0 (14.0)
Hypophosphatemia	0	5	1	0	2.3 (14.0)
Hypokalemia	5	0	1	0	2.3 (14.0)
Constipation	4	1	0	0	0 (11.6)
Peripheral sensory neuropathy	4	1	0	0	0 (11.6)
LDH increased	5	0	0	0	0 (11.6)
Hypermagnesemia	0	0	3	0	7.0 (7.0)
Neutrophil count decreased	0	4	0	0	0 (9.3)
Dizziness	2	1	1	0	2.3 (9.3)
Nasal mucositis	3	1	0	0	0 (9.3)
Paronychia	1	0	1	0	2.3 (4.7)
Dehydration	0	0	1	0	2.3 (2.3)
Hand foot syndrome	0	1	0	0	0 (2.3)
Acute renal failure	0	0	1	0	2.3 (2.3)